Hormonal
GLP-1 receptor agonists (e.g., liraglutide, semaglutide) induce significant weight loss in individuals with obesity by suppressing appetite and reducing energy intake through central nervous system mechanisms.
GLP-1 receptor agonists like semaglutide and liraglutide are highly effective pharmacological interventions for obesity that work by targeting the biological drivers of weight gain, specifically by suppressing appetite and reducing energy intake. They are administered via injection (daily or weekly) and have shown substantial weight loss in clinical trials. For those who struggle with injections, oral alternatives are in development. While currently expensive and less accessible in some regions, they represent a significant advancement over lifestyle changes alone for managing obesity and its comorbidities.
liraglutide and semaglutide have demonstrated remarkable efficacy in clinical trials, leading to substantial weight reductions (Pi-Sunyer et al 2015; Wilding et al 2021) by suppressing appetite and reducing energy intake (Friedrichsen et al 2021)
Why this rating
The paper cites multiple large-scale randomized controlled trials (e.g., Pi-Sunyer 2015, Wilding 2021) and recognizes the work with a major clinical award.
Source
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
Yu-Fei Zhou et al. · Current Medicine · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →